Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04780841 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
A Phase 2 study of Hyperkalemia, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 6
- Study locations
NCT04780841 is a Phase 2 study of Hyperkalemia that has completed, run by Ardelyx. The registered enrollment target is 109 participants, above the 48-participant average among 8 other Hyperkalemia trials with a reported enrollment target (127% higher). The trial reports 6 study locations across 4 states.
The verdict
NCT04780841, a Phase 2 study of Hyperkalemia, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RDX013
Study Locations (6)
Florida
- Horizon Research Group LLC - Coral Gables
- Panax Clinical Research LLC - Miami Lakes
- South Florida Research Phase I-IV; Inc. - Miami Springs
Louisiana
- NW Louisiana Nephrology Assoc - Shreveport
Missouri
- Clinical Research Consultants - Kansas City
North Carolina
- Mountain Kidney & Hypertension Associates - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2022-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04780841
The ClinicalTrials.gov registry entry for NCT04780841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 8 other Hyperkalemia trials with a reported enrollment target (127% higher). The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperkalemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04780841 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Louisiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT04780841 about?
NCT04780841 is a clinical study titled "A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia". The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels
What is the current status of trial NCT04780841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2021-01-11. Estimated completion is 2022-03-03.
What conditions does trial NCT04780841 study?
This clinical trial studies the following conditions: Hyperkalemia.
What interventions are being tested in trial NCT04780841?
The interventions under investigation include: Placebo (DRUG), RDX013 (DRUG).
Who is sponsoring clinical trial NCT04780841?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04780841 being conducted?
This trial has 6 study locations across Florida, Louisiana, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperkalemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
RECRUITING · Phase 2
-
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
COMPLETED · Phase 2
-
Evaluation of Patiromer in Heart Failure Patients
COMPLETED · Phase 2
-
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
RECRUITING
-
Adding Urea to the Final Dialysis Fluid
RECRUITING · Phase 1
-
Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.